NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.

Active, not recruiting

Plain-English translation of NCT06379217 on ClinicalTrials.gov ↗ · Source last updated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

Trial locations(9 sites)

United States

Nebraska Cancer Specialists, Omaha, Nebraska

Memorial Sloan Kettering Cancer Ctr, New York, New York

France

Novartis Investigative Site, Nantes

Germany

Novartis Investigative Site, München

Novartis Investigative Site, Rostock